Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.130
-0.100 (-4.48%)
Feb 21, 2025, 4:00 PM EST - Market closed
Annovis Bio Employees
As of December 31, 2023, Annovis Bio had 16 total employees, including 6 full-time and 10 part-time employees. The number of employees increased by 11 or 220.00% compared to the previous year.
Employees
16
Change (1Y)
11
Growth (1Y)
220.00%
Revenue / Employee
n/a
Profits / Employee
-$2,558,694
Market Cap
40.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ANVS News
- 3 days ago - Annovis to Host Patients' Live Forum on February 27, 2025 - GlobeNewsWire
- 15 days ago - Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 17 days ago - Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease - GlobeNewsWire
- 17 days ago - Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - GlobeNewsWire
- 19 days ago - Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering - GlobeNewsWire
- 21 days ago - Annovis Bio, Inc. Announces Proposed Public Offering - GlobeNewsWire
- 5 weeks ago - Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - GlobeNewsWire
- 2 months ago - Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace - GlobeNewsWire